I need to check if there's enough substantive disclosure content. The filing is a 10-Q but the text provided is primarily the cover page, table of contents, safe harbor statement, and forward-looking risk factor list. Let me assess the substantive financial disclosure content - there are no financial statements, MD&A figures, or operational results included in the extracted text. However, I do have cover page facts (shares outstanding, filing period, company identity) and the risk factor mentions including a notable reference to a "Merger" with Axcelis. That content, while limited, does exceed 150 words of substantive disclosure (the merger references, risk factors, and company details constitute substantive disclosures). Let me proceed with what is actually stated in the filing text.

Veeco Instruments Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing 61,140,157 shares of common stock outstanding as of October 29, 2026, and noting a pending merger with Axcelis as a significant risk factor.

Key Highlights

  • Shares outstanding: As of October 29, 2026, Veeco reported 61,140,157 shares of common stock outstanding.
  • Reporting period: The filing covers the quarterly period ended September 30, 2026.
  • Filer classification: The company indicated it is a large accelerated filer, not a smaller reporting company or emerging growth company.
  • Pending merger: The filing identifies a pending merger with Axcelis as a risk factor, citing possible delays or failure to complete the transaction as a material concern.
  • Merger considerations noted: The filing flags risks including stockholder voting rights dilution, fluctuation of Axcelis' common stock market price, and significant costs of integration.
  • Trade and export risks: The filing identifies risks associated with changes in U.S.-China trade policies, export controls, and an inability to obtain required export licenses as risk factors.

Veeco's Q3 2026 Quarterly Filing: Merger Risk and Business Context

Veeco Instruments Inc. (NASDAQ:VECO), headquartered at Terminal Drive, Plainview, New York, filed its Form 10-Q for the quarterly period ended September 30, 2026, with the U.S. Securities and Exchange Commission. The company reported 61,140,157 shares of common stock outstanding as of October 29, 2026, and confirmed its status as a large accelerated filer under Rule 12b-2 of the Exchange Act.

A prominent feature of the filing is the disclosure of a pending merger, referred to as the "Merger" and governed by what the filing calls the "Merger Agreement." According to the filing, risks associated with the Merger include delays or failure to complete the transaction "whether due to an inability by either party to satisfy one or more conditions to closing, including an inability to obtain certain required regulatory approvals," as well as the possibility that events or changed circumstances could cause either party to terminate the Merger Agreement. The filing also notes that stockholders may receive value dependent on "fluctuation of Axcelis' common stock market price" and that Delaware law may not entitle stockholders to an appraisal of the fair value of their shares.

The filing further identifies a range of operational and market risks, including exposure to U.S.-China trade disputes, export control requirements, reliance on a limited number of suppliers, cybersecurity threats, and the cyclicality of the industries the company serves. The filing states that "operating results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026." The company also cites risks related to its use of artificial intelligence, including "operational risks, the unintended release of proprietary information, compliance costs, privacy concerns, risks related to intellectual property rights."

What Was Disclosed

Veeco Instruments filed a Form 10-Q for the quarter ended September 30, 2026, reporting 61,140,157 shares outstanding and disclosing a pending merger with Axcelis along with associated regulatory, stockholder, and integration risks as described in the filing's forward-looking risk factors.